In This Story
The Nasdaq and other major stock market indexes dipped Wednesday after underwhelming earnings reports from Google parent Alphabet (GOOGL-7.81%) and chipmaker Advanced Micro Devices (AMD-6.88%). Other tech stocks such as Apple (AAPL-0.59%), Amazon (AMZN-2.51%), and Tesla (TSLA-3.88%) were also in the red.
Suggested Reading
Google’s AI principles are changing. Here’s what to know
Suggested Reading
In the afternoon, the tech-heavy Nasdaq was down about 0.05%, while the Dow Jones Industrial Average and S&P 500 added about 0.28% and 0.13%, respectively.
Alphabet and AMD stock falls after missing revenue
Shares of Alphabet (GOOGL-7.81%) fell more than 7% as the tech giant missed Wall Street’s earnings expectations for the fourth quarter despite “robust momentum across the business.” The Google parent reported revenues of $96.5 billion for the fourth quarter — a 12% increase year-over-year. Alphabet reported earnings of $2.15 per share, up 31% from the previous year, and net income of $26.5 billion for the quarter ended in December.
The company was expected to report revenues of $96.7 billion for the fourth quarter of 2024, according to analysts’ estimates compiled by FactSet (FDS+0.24%). Net income was expected at $26.2 billion, while analysts estimated earnings of $2.13 per share.
Shares in chipmaker Advanced Micro Devices (AMD-6.88%) fell 7% after the company’s fourth-quarter data center revenue missed expectations.
Disney is starting to shed streaming subscribers
Disney’s (DIS-1.95%) streaming business once again turned a profit last quarter. But its flagship platform is starting to lose subscribers.
The House of Mouse on Wednesday released its fiscal first-quarter results, with growth being driven primarily by the company’s box office dominance and profit gains in its streaming business. After rising 2.5% in the morning, the company’s shares were down 1.63% in the afternoon.
The Ozempic boom is slowing down
Sales of Novo Nordisk’s (NVO+3.70%) blockbuster weight loss drug Wegovy doubled in the fourth quarter, but the Danish pharmaceutical giant warns that sales growth for all its drugs — including Ozempic — is expected to slow in the coming year.
Wegovy sales skyrocketed 107% to 19.8 billion Danish Krone ($2.8 billion) in the fourth-quarter of 2024, compared with in 9.6 billion Danish Krone ($1.4 billion) during the the same period last year. The drug just beat analysts’ expectations of $2.7 billion, according to a consensus estimate from FactSet.
The company’s stock rose nearly 4.8% in the afternoon.
—Britney Nguyen and Bruce Gil contributed to this article.
